FDA Approves Immune Checkpoint Inhibitor for Head and Neck Cancer
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) to treat patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (combined positive score [CPS] ≥1) as determined by an FDA-approved test.
IVIG Effectively Increased Platelet Counts in Maternal Thrombocytopenia
A recent study that sought to evaluate the efficacy of intravenous immune globulin (IVIG) and identify predictors of platelet response in pregnant persons with moderate-to-severe thrombocytopenia, as well as to optimize clinical decisions and resource use, has found that IVIG effectively increases platelet counts.
FDA Approves Alzheimer’s Blood Test
The U.S. Food and Drug Administration has given marketing clearance to the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, a blood test to help diagnose Alzheimer’s disease for adults 55 and older who are showing signs and symptoms of the disease. It is the first test to be approved to aid in the early detection of the disease in the United States.
Study Finds RSV Vaccines Protect Older Adults with 75 Percent Effectiveness
A comprehensive new study published in JAMA Network Open revealed that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75 percent effectiveness against RSV-associated respiratory illness. In the study, researchers analyzed data from more than 787,000 older adults tested for RSV between October 2023 and April 2024, […]
FDA Approves New FcRN Blocker to Treat Generalized Myasthenia Gravis
Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis
FDA Approves Chikungunya Vaccine
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
Update on Rabies
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
Infant Botulism: A Patient’s Perspective
Susan Dabalos Anderson tells the story of her now-grown son receiving BabyBIG as an infant to treat baby botulism.
RSV Vaccine Prompts Robust Response in Older Recipients
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
Multiple Myeloma Patients Treated with Teclistamab May Benefit from IVIG Supplementation
Results of a recent study show patients with multiple myeloma undergoing teclistamab therapy may benefit from primary intravenous immune globulin supplementation, which appears to reduce the risk of high-grade infection.
